Beyond BRCA alterations, mutations in other genes involved in the homologous recombination (HR) pathway respond to PARP inhibitors therapy; further, alterations in upstream HR modulators such as in PTEN, may induce also a “BRCAness” phenotype that would potentially increase tumor sensitivity to PARP [75]. Here, PTEN is linked to neoplasm.